title: Trastuzumab: qui bono?
authors.affiliation: Affiliation of authors: Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.
authors.forename: Ian E
authors.initials: IE
authors.lastname: Krop
authors.forename: Harold J
authors.initials: HJ
authors.lastname: Burstein
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D047628:Estrogen Receptor alpha / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047628:Estrogen Receptor alpha; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C506487:ESR1 protein, human; C508053:ERBB2 protein, human